{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:26:57Z","timestamp":1790634417425,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jacc.2025.08.039","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:10:01Z","timestamp":1756282201000},"page":"1781-1801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2866-9414","authenticated-orcid":false,"given":"John W.","family":"Ostrominski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5169-117X","authenticated-orcid":false,"given":"Josephine","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair D.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-7882","authenticated-orcid":false,"given":"Michele","family":"Senni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5655-8201","authenticated-orcid":false,"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike D.","family":"Brinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Rohwedder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lay-Flurrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.08.039_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/eurheartj\/ehz388","article-title":"Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a mendelian randomization study","volume":"41","author":"Larsson","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.039_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1681\/ASN.2020050679","article-title":"Conventional and genetic evidence on the association between adiposity and CKD","volume":"32","author":"Zhu","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2025.08.039_bib3","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1093\/eurheartj\/ehab454","article-title":"Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and mendelian randomization studies","volume":"42","author":"Kim","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.039_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.039_bib5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jamacardio.2023.3241","article-title":"Prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, 1999-2020","volume":"8","author":"Ostrominski","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.08.039_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ekir.2017.01.009","article-title":"The obesity paradox in kidney disease: how to reconcile it with obesity management","volume":"2","author":"Kalantar-Zadeh","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jacc.2025.08.039_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pcad.2018.05.005","article-title":"Obesity and the obesity paradox in heart failure","volume":"61","author":"Horwich","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2025.08.039_bib8","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/eurheartj\/ehad083","article-title":"Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox","volume":"44","author":"Butt","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.039_bib9","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1093\/eurheartj\/ehaf057","article-title":"Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"46","author":"Peikert","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.039_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.039_bib11","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.039_bib12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.08.039_bib13","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.039_bib14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jacc.2024.10.111","article-title":"Finerenone, obesity, and heart failure with mildly reduced\/preserved ejection fraction: prespecified analysis of FINEARTS-HF","volume":"85","author":"Butt","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.08.039_bib15","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","article-title":"Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-\u03b3, and proinflammatory adipokines","volume":"117","author":"Guo","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.039_bib16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","article-title":"Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus\u2013associated obesity and vascular dysfunction","volume":"59","author":"Briones","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.08.039_bib17","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","article-title":"Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis","volume":"132","author":"Huby","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.039_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1161\/HYPERTENSIONAHA.115.06642","article-title":"Leptin induces hypertension and endothelial dysfunction via aldosterone-dependent mechanisms in obese female mice","volume":"67","author":"Huby","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.08.039_bib19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","article-title":"Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms","volume":"80","author":"Epstein","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2025.08.039_bib20","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.08.039_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2025.08.039_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2025.08.039_bib23","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.039_bib24","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.039_bib25","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.039_bib26","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.039_bib29","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.08.039_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1161\/CIR.0000000000000223","article-title":"Identification of obesity and cardiovascular risk in ethnically and racially diverse populations: a scientific statement from the American Heart Association","volume":"132","author":"Rao","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.039_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199509143331101","article-title":"Body weight and mortality among women","volume":"333","author":"Manson","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.039_bib32","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.ki.5002650","article-title":"Confounding: what it is and how to deal with it","volume":"73","author":"Jager","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2025.08.039_bib33","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.039_bib34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.08.039_bib35","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1001\/jama.2025.2704","article-title":"Prevalence of obesity with and without confirmation of excess adiposity among US adults","volume":"333","author":"Aryee","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.08.039_bib36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cell.2019.03.028","article-title":"Polygenic prediction of weight and obesity trajectories from birth to adulthood","volume":"177","author":"Khera","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jacc.2025.08.039_bib37","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.039_bib38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S2213-8587(22)00033-X","article-title":"Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study","volume":"10","author":"Kivim\u00e4ki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.08.039_bib39","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1056\/NEJMoa0801891","article-title":"General and abdominal adiposity and risk of death in Europe","volume":"359","author":"Pischon","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.039_bib40","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/eurheartj\/ehae206","article-title":"Body mass index, waist circumference, and mortality in subjects older than 80 years: a mendelian randomization study","volume":"24","author":"Lv","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.08.039_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.3604","article-title":"Sarcopenia and sarcopenic obesity and mortality among older people","volume":"7","author":"Benz","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2025.08.039_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.039_bib43","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.08.039_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.3665","article-title":"Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction according to body weight","author":"Butt","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.039_bib45","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/ejhf.792","article-title":"Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity: insight from the EMPHASIS-HF trial","volume":"19","author":"Olivier","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.039_bib46","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamacardio.2023.0711","article-title":"Effect of dapagliflozin on total heart failure events in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER trial","volume":"8","author":"Jhund","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.08.039_bib47","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.08.039_bib48","first-page":"745","article-title":"Efficacy and safety of finerenone in type 2 diabetes: a pooled analysis of trials of heart failure and chronic kidney disease","volume":"48","author":"Ostrominski","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.08.039_bib49","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae426","article-title":"Epidemiological risk factors for acute kidney injury outcomes in hospitalized adult patients: a multicenter cohort study","volume":"18","author":"Takeuchi","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jacc.2025.08.039_bib50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cardfail.2019.09.015","article-title":"Adverse renal response to decongestion in the obese phenotype of heart failure with preserved ejection fraction","volume":"26","author":"Reddy","year":"2020","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2025.08.039_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.03.042","article-title":"Obesity and risk of kidney outcomes in heart failure with preserved ejection fraction: a participant-level pooled analysis of 4 contemporary trials","volume":"13","author":"Lassen","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.08.039_bib52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41574-019-0310-7","article-title":"Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR Working Group on Visceral Obesity","volume":"16","author":"Ross","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jacc.2025.08.039_bib53","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1467-789X.2007.00411.x","article-title":"Does the relationship between waist circumference, morbidity and mortality depend on measurement protocol for waist circumference?","volume":"9","author":"Ross","year":"2008","journal-title":"Obes Rev"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725075059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725075059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T01:25:26Z","timestamp":1766193926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725075059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":51,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0735109725075059"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.039","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.08.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}